Evaluating changes in antibiotic prescriptions for Pseudomonas infections
Impact of Modifications to the Rendering of the Antibiogram on the Prescriptions of Meropenem in Pseudomonas Bacteremia
This study looks at how changes in antibiotic sensitivity reports have affected doctors' prescribing of Meropenem for patients with Pseudomonas infections.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Strasbourg, France Academic / other |
| Locations | 1 site (Strasbourg) |
| Trial ID | NCT06113107 on ClinicalTrials.gov |
What this trial studies
This study examines how modifications to the antibiogram at Strasbourg University Hospital have influenced the prescription patterns of Meropenem for Pseudomonas bacteremia. Following a change in the presentation of antibiotic sensitivity results, the study aims to assess whether these changes have led to an increase in inappropriate Meropenem prescriptions. By analyzing data from patients with positive blood cultures for Pseudomonas, the study seeks to understand the impact of these modifications on antibiotic stewardship practices. The observational nature of the study allows for real-world insights into prescribing behaviors in response to antibiogram changes.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with a positive blood culture for Pseudomonas spp. from June 2018 to November 2022.
Not a fit: Patients with Pseudomonas strains resistant to all first-line beta-lactams or Meropenem will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved antibiotic prescribing practices, reducing unnecessary use of Meropenem and enhancing patient outcomes.
How similar studies have performed: While this specific approach is novel, similar studies have shown that modifications in antibiotic stewardship can significantly impact prescribing patterns.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Major subject (≥18 years old) * Subject with a positive blood culture result for Pseudomonas spp identified in the microbiology laboratory of Strasbourg University Hospital during the period from June 1, 2018 to November 30, 2022 * Subject not opposing the reuse of their data for the purposes of this research. Exclusion Criteria: * Subject having expressed opposition to participating in the study, * Pseudomonas spp strain resistant to all first-line beta-lactams (Piperacillin-Tazobactam, Ceftazidime, Céfepime and Aztreonam). * Pseudomonas spp strain resistant to Meropenem. * Lack of information on the antibiotic treatment undertaken.
Where this trial is running
Strasbourg
- Service des Maladies Infectieuses et Tropicales - CHU de Strasbourg - France — Strasbourg, France (Recruiting)
Study contacts
- Study coordinator: Yvon RUCH, MD
- Email: yvon.ruch@chru-strasbourg.fr
- Phone: 33 3 69 55 12 19
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.